Clinical Trials Browser

Phase 3 × Completed × pertuzumab × Clear all

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT05415215 2026-02-10

ProHer

Phase 3 Completed

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Phase 3 Completed

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

Phase 3 Completed

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT05283837 2024-07-18

A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)

Phase 3 Completed

Breast Neoplasms

NCT03493854 2024-06-26

FeDeriCa

Phase 3 Completed

500 enrolled 28 charts 2 FDA

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Phase 3 Completed

1,095 enrolled 46 charts

Breast Neoplasms

NCT02586025 2023-05-22

PEONY

Phase 3 Completed

329 enrolled 33 charts

Breast Neoplasms

NCT02896855 2021-12-16

PUFFIN

Phase 3 Completed

243 enrolled 23 charts

Breast Neoplasms

NCT01572038 2020-09-25

PERUSE

Phase 3 Completed

1,436 enrolled 53 charts

Breast Neoplasms

NCT02402712 2019-09-06

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT02019277 2018-09-13

SAPPHIRE

Phase 3 Completed

50 enrolled 18 charts

Breast Neoplasms

NCT01026142 2018-08-14

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Phase 3 Completed

452 enrolled 18 charts

Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Phase 3 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01684878 2017-05-23

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Phase 3 Completed

208 enrolled 19 charts

Ovarian Neoplasms